iEmoji Feeds @Santhosh Ambika (RenoHemonc)
1.
Santhosh Ambika
@RenoHemonc
️ @hoperugo’s “Roadmap for Early Triple Negative Breast Cancer” #SGBCC2023 pic.twitter.com/EngrqthF4F
17 Mar 23
copy & paste +upvote -downvote 🗺️ @hoperugo’s “Roadmap for Early Triple Negative Breast Cancer” #SGBCC2023 https://t.co/EngrqthF4F
2.
Santhosh Ambika
@RenoHemonc
Very young women do poorly from #Breastcancer . Here we characterise oncogenic drivers from >1200 patients BC sa… twitter.com/i/web/status/1…
04 Feb 23
copy & paste +upvote -downvote 🚩Very young women do poorly from #Breastcancer 🤔. Here we characterise oncogenic drivers from >1200 patients BC sa… https://t.co/ISY42cWygM
3.
4.
5.
6.
7.
Santhosh Ambika
@RenoHemonc
What to do when admitting a patient with lower GI bleeding
New, awesome guidelines from @SenguptaNeil
CTA if ong… twitter.com/i/web/status/1…
New, awesome guidelines from @SenguptaNeil
CTA if ong… twitter.com/i/web/status/1…
04 Feb 23
copy & paste +upvote -downvote What to do when admitting a patient with lower GI bleeding
🔥New, awesome guidelines from @SenguptaNeil
🔥CTA if ong… https://t.co/YuTfWnizK0
Santhosh Ambika
@RenoHemonc
new @myESMO #lungcancer guidelines for #biomarker driven therapies. 10 genomic alterations + more on the horizon… twitter.com/i/web/status/1…
Retweet of status by @christine_lovly
23 Jan 23
copy & paste +upvote -downvote ⬇️ new @myESMO #lungcancer guidelines for #biomarker driven therapies. 10 genomic alterations + more on the horizon… https://t.co/mmKoiYlW1t
Santhosh Ambika
@RenoHemonc
longer follow up (3 years) continues to show ctDNA is strongly associated with relapse (HR=6) and a 40% risk of… twitter.com/i/web/status/1…
Retweet of status by @tompowles1
05 Jul 22
copy & paste +upvote -downvote longer follow up (3 years) continues to show ctDNA is strongly associated with relapse (HR=6) and a 40% ⬇️ risk of… https://t.co/QsF1Q5HinM
Santhosh Ambika
@RenoHemonc
#OpenAccess Consensus Statement A clinical care pathway for von Hippel–Lindau (VHL) disease management develop… twitter.com/i/web/status/1…
Retweet of status by @VivekSubbiah
19 May 22
copy & paste +upvote -downvote 📍🚨 #OpenAccess Consensus Statement 👉🏼A clinical care pathway for von Hippel–Lindau (VHL) disease management develop… https://t.co/gsybvbB4YX
Santhosh Ambika
@RenoHemonc
MSH6
️Pathogenic variants in MSH6 cause #LynchSyndrome
️Lifetime #colorectalcancer risk is 10-44%
️Colonoscopy e… twitter.com/i/web/status/1…
️Pathogenic variants in MSH6 cause #LynchSyndrome
️Lifetime #colorectalcancer risk is 10-44%
️Colonoscopy e… twitter.com/i/web/status/1…
13 Mar 22
copy & paste +upvote -downvote MSH6
⚕️Pathogenic variants in MSH6 cause #LynchSyndrome
⚕️Lifetime #colorectalcancer risk is 10-44%
⚕️Colonoscopy e… https://t.co/ozbRZ11dtF
8.
9.
Santhosh Ambika
@RenoHemonc
Thrilled to announce that our paper is out @NatureMedicine!
We looked at the impact of nivolumab/ipilimumab +/-… twitter.com/i/web/status/1…
We looked at the impact of nivolumab/ipilimumab +/-… twitter.com/i/web/status/1…
Retweet of status by @NazliDizman
28 Feb 22
copy & paste +upvote -downvote 🥁Thrilled to announce that our paper is out @NatureMedicine!
We looked at the impact of nivolumab/ipilimumab +/-… https://t.co/8iCamY8G6S
Santhosh Ambika
@RenoHemonc
BFAST cohort C #ESMO21 was negative trial to liquid 🩸 biopsy. Be SLOW to wait test solid tumor. Liquid biopsy i… twitter.com/i/web/status/1…
Retweet of status by @FernandoOnco
20 Sep 21
copy & paste +upvote -downvote ⚠️BFAST cohort C #ESMO21 was negative ➖ trial to liquid 🩸 biopsy. Be SLOW to wait test solid tumor. Liquid biopsy i… https://t.co/gJa91q6aoR
...but wait! There's more!
1.
fakhright
@fakhright
astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*
14 Jan 13
copy & paste +upvote -downvote astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat* 🙈🙈🙊